Biolojic Design, Ltd.

Based in Rehovot, Israel and founded in 2009, Biolojic Design, Ltd. , dba Biolojic Design, is a biotechnology company that develops active human antibody therapeutics directed against functional epitopes. The CEO of Biolojic Design is Yanay Ofran. In January 2021, ATP, a life sciences venture capital firm, partnered with Biolojic Design and created Aulos Bioscience which is a new firm dedicated to the development of highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumours.

In March 2021, Biolojic Design started collaborating with Lilly, a healthcare company, providing its antibody platform powered by AI and developing a new antibody-based treatment for diabetes. According to the terms of the agreement, Biolojic Design can receive up to USD 121 million from Lilly, comprised of potential development and commercialisation milestones, a promissory note and tiered royalties. Focusing on autoimmune and immuno-oncology, the company’s team of researchers primarily develop an AI powered platform generating single and multi-specific human antibodies directed against predefined functional epitopes, thus providing new biological programmes and therapeutics. Its platform imitates the fashion in which the immune system creates antibodies by firstly searching for an existing human antibody predicted to be complementary to the epitope, followed by predicting the mutation that will improve complementarity to the target, and lastly designing a focused library and monitoring selection.